Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Pro Bono Bio PLC: SEQuaderma launches a campaign to address preconceptions based on people’s appearance
  • USA - English


News provided by

Pro Bono Bio

Nov 24, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

London, United Kingdom (PRWEB UK) 24 November 2015 -- SEQuaderma active dermatology products by Pro Bono Bio PLC, the world’s leading nanotechnology company offering health and lifestyle products, has launched a campaign, supported by the British Skin Foundation (BSF) aiming at supporting people that may be misjudged based on their appearance.

A new campaign launches today to challenge the way society responds to the appearance of others. The #TakeASEQondlook movement asks us pledge to value difference and acknowledge that split second judgements based on looks rather than understanding, can lead to hurt and rejection. In a world where image is king and our social connections require us to comment, it is far too easy to share instant responses that can cause harm. The #TakeASEQondlook mission calls for people to voice their support, by sharing stories, displaying the campaign badge on their social media posts and by taking part in what is hoped will be a significant survey into the impact of appearance on us all.

SEQuaderma asks us all to challenge preconceptions based on appearance and to respect individuality. The results from the survey will also form part of forthcoming research by the BSF into the psychological impact of skin conditions, which will be conducted on behalf of BSF and made possible through funding provided by SEQuaderma. Knowledge gained from the campaign will also be also shared with like-minded organisations that are dedicated to championing equality and the rights of individuals.

Phil Brady, Director of Fundraising at the British Skin Foundation says:
“We are pleased to be part of a big campaign like this and hope that it will bring acceptance of people who look slightly different, whether because of a skin condition or other visual difference. The survey will enable us to gain further insight into people’s personal challenges; the fundraising opportunities will help us fund research into the psychological effects of living with skin conditions and visual differences.”

Michael Earl COO of Pro Bono Bio said “We are delighted to be launching this exciting initiative, which was inspired by some of the stories we have encountered during the development of the SEQuaderma range of dermatology products.The SEQuaderma range adheres closely to our company motto of “Do No Harm”. With Flexiseq we have been able to reduce the drug burden of NSAIDs for people with joint pain. With SEQuaderma we aim to reduce the burden of drugs such as steroids for people with various dermatoses and provide a really effective non-drug alternative to other cosmetic treatments that simply paint over the problem. We continue to bring Safe, Effective, Quality (SEQ) products to the market to change people’s lives for the better.”

Find out more at http://www.sequaderma.com

For further information please contact:

John Mayo    
Pro Bono Bio
+44 20 7291 5456                                                    
karen.frost(at)pbbio(dot)com

Michael Earl
Pro Bono Bio
+44 20 7291 5446
lucy.parker(at)pbbio(dot)com

About SEQuaderma™:
SEQuaderma is a range of active dermatology products that provide solutions for those living with eczema, seborrhoeic dermatitis, acne, rosacea and having the visible signs of chronological and photoageing. All five products incorporate Sequessome Technology that offer simple, scientific solutions to help alleviate a range of common skin conditions. Clinical trials have shown that SEQuaderma products produce demonstrable improvements in skin health, comfort and appearance. SEQuaderma products address each stage of a skin condition’s cycle from cause, to symptoms, to recurrence. They can be used over extended periods, on their own or in combination with prescription medicine. They contain no drugs so have an excellent safety profile, low risk of skin irritation, and low risk of interaction with other medications.

SEQuaderma products are unique – they are able to penetrate deeper into the skin tissue due to the use of patented Sequessome Technology®. Here they both hydrate the skin and supply key nutrients to support the skin’s natural recovery process.

About the British Skin Foundation
The British Skin Foundation is the UK’s only charity dedicated to skin research. The BSF raises money to fund research for cures for skin diseases incl. skin cancer, providing hope for the eight million people living in the UK with a skin condition.

About Pro Bono Bio:
Pro Bono Bio plc is the world’s leading nanotechnology company offering health and lifestyle products, headquartered in London with operations in Europe, North America, Africa and Asia.

Pro Bono Bio’s first product, Flexiseq gel, is a medical device that safely targets joint pain by a unique drug-free lubricating action. It was launched in 2012 and is currently available in the UK, Irish Republic, Germany, France, Malta, South Africa, Hong Kong, Malaysia and Singapore.

Nick Baverstock, Pro Bono Bio, http://www.sequaderma.com, +44 7928043360, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.